
PHAR: Is Pharming Group N.V. Halal?
Pharming Group N.V.
$13.77
+0.84%
Market Cap: 972.5M
Compliance Status
Halal
Screened on Aug 31, 2026 · AAOIFI Standard 21
Acceptable
Is Pharming Group N.V. (PHAR) halal? Halal. Based on AAOIFI screening, Pharming Group N.V. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 67/100 (Grade: B).
Quote this verdict
HalalScreener rates Pharming Group N.V. (PHAR) Halal, 67/100, grade B under AAOIFI Standard 21, screened Aug 31, 2026. Source: https://halalscreener.app/en/stock/PHAR
Business activity
What the company sells is permissible.
Company debt
Well clear of the limitHow much the company borrows, compared to its total value. AAOIFI allows up to 30%.
What this means for you
You can own PHAR
It passes both the business activity and financial ratio screens under AAOIFI Standard 21.
Purification amount is Pro
We have screened PHAR's prohibited income, but the exact share you would need to purify is part of Pro.
About Pharming Group N.V.
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Sector: Healthcare · Industry: Biotechnology
Shariah Compliance Status
Compliance History
Halalnow
since Aug 2026
Doubtful
until the change above
Halal
until the change above
Tracked since May 2026. Updates automatically on each re-screen.
More Healthcare Stocks
Track PHAR and 6,200+ stocks with AI insights
Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.
Frequently Asked Questions
Is Pharming Group N.V. (PHAR) halal to invest in?
Why did Pharming Group N.V. get a B compliance rating?
What could change Pharming Group N.V.'s Shariah verdict?
How often is Pharming Group N.V. re-screened for Shariah compliance?
Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.